Using various mutants of p53 and mdm2, we demonstrate here that both the DNA binding and transactivation function of p53 are required for ASPP1 and ASPP2 to stimulate the apoptotic functions of p53. Mdm2 and mdmx prevent ASPP1 and ASPP2 from stimulating the apoptotic function of p53 by binding and inhibiting the transcriptional activity of p53. Importantly, mdm2 and mdmx can prevent the stimulatory effects of ASPP1 and ASPP2 without targeting p53 for degradation. These data provide a novel mechanism by which mdm2 and mdmx act as potent inhibitors of p53. Keywords: ASPP; p53; mdm2; mdmX; apoptosis; transactivation One of the most important tumor suppression function of p53 is perhaps its ability to induce apoptosis in response to DNA damage. As a transcription factor, p53 induces apoptosis by transactivating and transrepressing a set of apoptosis-regulating genes (Vousden and Lu, 2002; Slee et al., 2004) . In addition, p53 also induces apoptosis independent of its DNA binding and transcriptional activity (Caelles et al., 1994; Moll and Zaika, 2001) . Its activators and inhibitors tightly regulate the apoptotic function of p53 in vivo (Momand et al., 1992; Avantaggiati et al., 1997; Lill et al., 1997) . The identification of the ASPP family of proteins provided a novel mechanism by which the apoptotic function of p53 is regulated (Samuels-Lev et al., 2001; Bergamaschi et al., 2003). The binding of ASPP1 and ASPP2 stimulates the apoptotic function of p53 by enhancing its DNA binding and transactivation activity of proapoptotic genes such as Bax and PIG3, but not mdm2 and p21waf1 (Samuels-Lev et al., 2001) . However, there is increasing evidence suggesting that p53 can induce apoptosis through both transcriptionally dependent and independent pathways. In vitro, cytoplasmic p53 can directly activate Bax to induce apoptosis (Chipuk et al., 2004) . In cells, when p53 is located to the mitochondria it also induces apoptosis independent of its DNA binding and transcriptional activity (Mihara et al., 2003) . Interestingly, ASPP1 and ASPP2 are predominantly located in the cytoplasm. Perhaps, the interaction between the cytoplasmic p53 and ASPP1 or ASPP2 may induce apoptosis independent of the transcriptional activity of p53.
One of the most important tumor suppression function of p53 is perhaps its ability to induce apoptosis in response to DNA damage. As a transcription factor, p53 induces apoptosis by transactivating and transrepressing a set of apoptosis-regulating genes (Vousden and Lu, 2002; Slee et al., 2004) . In addition, p53 also induces apoptosis independent of its DNA binding and transcriptional activity (Caelles et al., 1994; Moll and Zaika, 2001) . Its activators and inhibitors tightly regulate the apoptotic function of p53 in vivo (Momand et al., 1992; Avantaggiati et al., 1997; Lill et al., 1997) . The identification of the ASPP family of proteins provided a novel mechanism by which the apoptotic function of p53 is regulated (Samuels-Lev et al., 2001; Bergamaschi et al., 2003) . The binding of ASPP1 and ASPP2 stimulates the apoptotic function of p53 by enhancing its DNA binding and transactivation activity of proapoptotic genes such as Bax and PIG3, but not mdm2 and p21waf1 (Samuels-Lev et al., 2001) . However, there is increasing evidence suggesting that p53 can induce apoptosis through both transcriptionally dependent and independent pathways. In vitro, cytoplasmic p53 can directly activate Bax to induce apoptosis (Chipuk et al., 2004) . In cells, when p53 is located to the mitochondria it also induces apoptosis independent of its DNA binding and transcriptional activity (Mihara et al., 2003) . Interestingly, ASPP1 and ASPP2 are predominantly located in the cytoplasm. Perhaps, the interaction between the cytoplasmic p53 and ASPP1 or ASPP2 may induce apoptosis independent of the transcriptional activity of p53.
To understand how ASPP1 and ASPP2 stimulate the apoptotic function of p53, various p53 mutants were used to test the effects of ASPP1 and ASPP2 on p53 activity. We first examined the effect of ASPP1 and ASPP2 on a p53 fusion protein, p53-Gal4. The transactivation domain (first 42 amino acids) of p53 was fused with the DNA binding domain of the transcription factor Gal4. The p53-Gal4 fusion protein binds to DNA containing a Gal4 site but not a p53 site. If ASPP1 and ASPP2 specifically stimulate the transactivation function of p53 and regulate promoter specificity through protein-protein interaction, the coexpression of ASPP1 or ASPP2 should not influence the transactivation function of p53-Gal4 on a Gal4 reporter since p53-Gal4 lacks the DNA binding domain of p53. On the other hand, if ASPP1 and ASPP2 stimulate the transactivation function of p53 through the transactivation domain of p53 and independent of their interactions with p53, ASPP1 or ASPP2 may still be able to enhance the transactivation function of the p53-Gal4 fusion protein. Neither the expression of ASPP1 nor ASPP2 enhanced the transactivation function of p53-Gal4 on the Gal4 reporter, despite the similar expression levels of ASPP1 and ASPP2 (Figure 1a) . Hence, the DNA binding domain of p53 is required for ASPP1 and ASPP2 to enhance the transactivation function of p53. The failure of ASPP1 or ASPP2 to induce the transactivation and apoptotic function of a DNA binding-defective p53 mutant, p53 H175, illustrated further that the DNA binding activity of p53 is critical for ASPP1 and ASPP2 to stimulate both the transactivation and apoptotic functions of p53 (Figure 1b and c) .
To determine whether ASPP1 and ASPP2 can stimulate the apoptotic function of p53 independently of transcription, we investigated the effects of ASPP1 and ASPP2 on the transactivation and apoptotic function of a DNA binding-competent but transcription-defective mutant of p53, p53(22-23) (Lin et al., 1994) . In most studies, the transactivation and apoptotic function of p53(22-23) are minimal. However, this mutant can display both activities under certain conditions (Tang et al., 2004) . Coexpression of ASPP1 or ASPP2 significantly enhanced the transactivation function of wild-type p53, but not p53(22-23) (Figure 2a and  b) . Similarly, coexpression of ASPP1 and ASPP2 failed to enhance the apoptotic function of p53(22-23), even though under the same conditions, the apoptotic function of wild-type p53 was greatly stimulated (Figure 2c ). These results demonstrated that the transcriptional activity of p53 is vital for ASPP1 and ASPP2 to stimulate both the transactivation and apoptotic functions of p53. 
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Rescuing the embryonic lethality of mdm2 and mdmx with p53 null background reinforced the biological importance of mdm2 and mdmx as inhibitors of p53 in vivo (de Oca Luna et al., 1995; Jones et al., 1995; Parant et al., 2001) . The binding of mdm2 or mdmx to p53 on residues 17-25, located within the transcriptional domain of p53, regulates the transactivation and transrepression functions of p53 (Chen et al., 1993; Oliner et al., 1993; Bottger et al., 1999) . The binding of mdm2 to p53 also targets p53 for degradation (Haupt et al., 1997; Kubbutat et al., 1997) . Therefore, mdm2 may prevent ASPP1 or ASPP2 from stimulating the apoptotic function of p53 by targeting p53 for degradation. On the other hand, if ASPP1 and ASPP2 enhance p53 activity through transcriptional-dependent pathway, both mdm2 and mdmx may prevent ASPP1 and ASPP2 from stimulating the activities of p53 without targeting p53 for degradation. This was first tested by comparing the ability of mdm2 and an mdm2 mutant, mdm2(D222-437), to inhibit the activities of p53 in the presence of ASPP1 and ASPP2. The mutant mdm2, mdm2(D222-437), binds p53 and inhibits its transactivation function without targeting p53 for degradation (Kubbutat et al., 1997) . As predicted, mdm2 inhibited the transactivation function of p53. Interestingly, the enhanced transactivation function of p53 by ASPP1 and ASPP2 was abolished in the presence of mdm2 or its mutant, mdm2(D222-437) (Figure 3a) . Similar results were also obtained with regard to the apoptotic function of p53. The coexpression of mdm2 or mdm2(D222-437) not only prevented ASPP1 and ASPP2 from stimulating the apoptotic function of p53, it also inhibited the apoptotic function of p53 alone (Figure 3b ). All these demonstrated that mdm2 could prevent ASPP1 and ASPP2 from stimulating the transactivation and apoptotic function of p53 without targeting p53 for degradation.
In agreement with this, the coexpression of mdmx, a family member of mdm2, which can bind p53 without targeting it for degradation (Jackson and Berberich, 2000; Stad et al., 2001) , inhibited the apoptotic function of p53. The expression of mdmx Figure 1 DNA binding activity of p53 is required for ASPP1 and ASPP2 to stimulate specifically the transactivation (a and b) and apoptotic (c) function of p53. Saos-2 cells were plated 24-48 h prior to transfection (5 Â 10 5 cells in 6 cm dishes for transactivation assays (a and b) or 1.8 Â 10 6 cells in 10 cm plates for FACS analysis to measure apoptosis (c). All cells were transfected with indicated plasmids using calcium phosphate method. For transactivation assays, 1 mg of reporter plasmid responsive to p53 or p53-Gal4 (Bax-luc and Gal4-luc, respectively), 50 ng of p53 wt, p53(1-13)Gal4, p53(1-42)Gal4, or p53 H175, and 4 mg of ASPP1 or ASPP2 as indicated. Plasmids p53(1-13)Gal4 and p53(1-42)Gal4 contain amino acids 1-13 and 1-42 (containing DO.1 epitope) of p53, respectively. Cells were lysed in 1 Â Reporter Lysis Buffer (Promega) 16-24 h after transfection and assayed using the Luciferase Assay kit (Promega, WI, USA). The fold activation of a particular reporter was determined by the activity of the transfected plasmid divided by the activity of vector alone. The bar graphs show the effects of ASPP1 and ASPP2 on the transactivation function of p53 on promoters of Bax and not Gal4-Luc. For FACS analysis, all cells were transfected with 2 mg of a plasmid expressing CD20 as a transfection marker. A measure of 1 mg of p53 wt or 2 mg of p53 H175 were coexpressed in the presence or absence of 10 mg of ASPP1 and ASPP2 as indicated. At 36 h after the transfection, both attached and floating cells were harvested and analysed as described (Bergamaschi et al., 2003) . The expression levels of ASPP1, ASPP2, p53, or p53 H175 were detected with antibodies V5, DX.5410, or DO1, respectively. The mean values were derived from at least three independent experiments For figure refer page 3837 To investigate whether binding is required for mdm2 to prevent ASPP1 and ASPP2 from stimulating the activities of p53, various mdm2 mutants were used to study their effects on p53 activity in the presence or absence of ASPP2. As shown in Figure 4 , the expression of wild-type mdm2 or few other p53 binding mutants, mdm2(1-223), mdm2(1-273), and mdm2(1-441), inhibited the apoptotic function of p53. The expression of mdm2 or the above-mentioned mutants also prevented ASPP2 from enhancing the apoptotic function of p53. Interestingly, the expression of an N-terminal-truncated p53 binding-defective mutant mdm2, mdm2(218-491), was unable to inhibit the apoptotic function of p53. Similarly, it was defective in preventing ASPP2 from stimulating the apoptotic function of p53 (Figure 4a and  b) . The failure of mdm2(218-491) to prevent ASPP2 from stimulating p53 was not due to a lack of protein expression ( Figure 4c) . Therefore, binding to p53 is required for mdm2 to prevent ASPP2 from stimulating the activities of p53. The ability for mdm2 to target p53 for degradation is not required, since mdm2(1-223), mdm2(1-273), and mdm2(1-441) are all defective in targeting p53 for degradation. Taken together, mdm2 prevents ASPP1 and ASPP2 from stimulating the activities of p53 through its ability to inhibit the transcriptional activity of p53.
The finding that inhibiting the transcriptional activity of p53 was sufficient for mdm2 and mdmx to prevent the stimulatory effects of ASPP1 and ASPP2 is particularly important as high levels of mdm2 and mdmx have been detected in human tumors, some of which express wildtype p53 (Ramos et al., 2001; Cordon-Cardo et al., 1994; Danovi et al., 2004) . The study shown here suggests that even when mdm2 loses its ability to target p53 for degradation, it can still inhibit p53-induced apoptosis very effectively and this also provides another molecular explanation for the oncogenic effect of mdmx. All these data reinforce the notion that the transcriptional activity of p53 plays a critical role in its ability to induce apoptosis and tumor suppression. Therefore, mdm2 and mdmx are oncogenic by both targeting p53 for degradation as well as by preventing the transcriptional activity of p53. Prevention of ASPP1 and ASPP2 from stimulating p53 D Bergamaschi et al
